Skip to content
Gene2Rx home

Try

Loading…

Search couldn't load. Check your connection and try again, or use the medication lookup.

No pages match .

The medication lookup checks any medication by name, including ones without their own page.

Get my report
In the Full Report

Oliceridine

Oliceridine (Olinvyk) is an intravenous opioid for adults with acute pain severe enough to need one. Unlike codeine and tramadol, it does not need CYP2D6 to become active: the enzyme helps clear it, so CYP2D6 poor metabolizers have about twice the usual exposure. The FDA label says poor metabolizers may need less frequent doses and close monitoring for breathing problems and sedation; CPIC has no guideline for this drug.

At a glance
Brand namesOlinvyk
Used forAcute pain in adults severe enough to need an intravenous opioid when other treatments are inadequate
GenesCYP2D6
GuidanceFDA label (sections 5.6, 8.8 and 12.5) [1]; no CPIC guideline
Gene2Rx coverageConsumer DNA tests and whole-genome sequencing.

How oliceridine works

Oliceridine is a full opioid agonist that is relatively selective for the mu-opioid receptor. It is given only intravenously, by a healthcare provider or through a patient-controlled pump, and pain relief starts within 2 to 5 minutes. The label puts an initial 1 mg dose at roughly the strength of 5 mg of intravenous morphine. Total daily doses are capped at 27 mg because higher amounts may prolong the QT interval of the heart's rhythm, and use beyond 48 hours was not studied in controlled trials [1].

The liver breaks oliceridine down mainly through CYP3A4 and CYP2D6, with small contributions from CYP2C9 and CYP2C19. None of the metabolites has meaningful activity at the opioid receptor. Oliceridine's half-life is 1.3 to 3 hours, while its inactive metabolites linger for about 44 hours [1]. Because the drug itself does the work, reduced CYP2D6 activity means more drug and stronger or longer effects, the opposite of what happens with codeine.

How CYP2D6 affects oliceridine

CYP2D6 poor metabolizers carry two non-working copies of the gene and have little or no enzyme activity. The label estimates that 3 to 10% of White people, 2 to 7% of African Americans and under 2% of Asian people are poor metabolizers [1]. The codeine page explains how CYP2D6 results are classified.

The label reports that poor metabolizers clear oliceridine at about half the rate of other people, and that their total exposure (area under the curve) is about twice as high. Blocking CYP3A4 as well raises it further: in four poor metabolizers who took the CYP3A4 inhibitor itraconazole, exposure rose by about 80% more and clearance fell to about 30% of that in other metabolizer types [1]. The label gives no figures for intermediate or ultrarapid metabolizers.

What the FDA label recommends

For patients who are known or suspected to be CYP2D6 poor metabolizers, based on genotype or on past experience with other CYP2D6-processed drugs, the FDA label says less frequent dosing may be needed. It tells clinicians to monitor these patients closely and to base later doses on the severity of pain and the response [1]. The FDA's Table of Pharmacogenetic Associations lists this finding in its first section, where the data support management recommendations, citing a higher risk of respiratory depression and sedation [2]. CPIC has not published a guideline; its gene-drug list gives the pair only a provisional level [3].

CYP2D6 results and oliceridine
ResultWhat it meansGuideline recommendation
Ultrarapid MetabolizerNo FDA statement.No genotype-specific guidance; usual dosing.
Normal MetabolizerNo FDA statement.No genotype-specific guidance; usual dosing.
Intermediate MetabolizerNo FDA statement.No genotype-specific guidance; usual dosing.
Poor MetabolizerAbout twice the usual exposure, with a higher risk of respiratory depression and sedation.FDA: less frequent dosing may be needed; monitor closely and base later doses on pain and response.
Indeterminate or not availableAn allele was found whose function is uncertain or unknown, so no phenotype can be given.No genotype-specific guidance; usual starting dose.

Want to know what your genetics say about how you'll respond to Oliceridine?

A Gene2Rx report reads your own DNA to show how it may affect your response to Oliceridine and your other medications.

Using your result

Oliceridine is given intravenously under medical supervision, so the main use of a poor metabolizer result is to let the care team know in advance, for example before planned surgery. Bring a full medicine list too, because other drugs can have the same effect as the genotype. The label names paroxetine, fluoxetine, quinidine and bupropion as CYP2D6 inhibitors that can raise oliceridine levels, and erythromycin, ketoconazole and ritonavir as CYP3A4 inhibitors. Blocking both pathways at once, or being a poor metabolizer who takes a CYP3A4 inhibitor, raises levels the most [1].

A normal metabolizer result does not change the usual dosing or the ordinary risks of an opioid. Do not start, stop or change any medicine because of a genetic result without talking to your prescriber.

What this result cannot tell you

Consumer arrays (23andMe, AncestryDNA, MyHeritage) are not clinical-grade tests, and their raw data is labeled not for medical use. They read fixed positions, and Gene2Rx uses imputation to infer some variants that were not measured directly. A normal result means none of the assessed variants was found among the positions your data covers; it cannot rule out a variant at a position the data does not cover. The label's poor metabolizer figures come from pharmacokinetic studies in healthy volunteers, and it offers none for other groups.

Common questions

Does a poor metabolizer result mean I cannot receive oliceridine?

No. The label allows it with less frequent dosing and close monitoring (see What the FDA label recommends).

Is oliceridine affected by CYP2D6 the same way as codeine?

No. Codeine needs CYP2D6 to become active, so poor metabolizers get less effect; oliceridine is active itself, so poor metabolizers get more.

Sources and further reading

  1. Olinvyk (oliceridine) injection: prescribing information (Trevena). DailyMed. Dosing, metabolism, CYP2D6 poor metabolizer data and interactions.
  2. FDA. Table of Pharmacogenetic Associations. Oliceridine entry for poor metabolizers.
  3. CPIC. Gene-drug pairs and CPIC levels (spreadsheet). Provisional level, no guideline.
Disclaimer: This document is for informational purposes only and is not a substitute for medical advice. Clinical decisions should be made by a qualified healthcare professional.

Interested in learning more about how your genetics may affect your response to medication? Get started with Gene2Rx today.

I'm Interested